Cabiralizumab (FPA 008) is a monoclonal antibody targeting CSF1R (Colony Stimulating Factor 1 Receptor), designed to modulate the immune system by enhancing T cell infiltration and promoting antitumor immune responses. This antibody effectively inhibits the activation of osteoclasts, thereby preventing bone destruction, making it a valuable tool in the study of rheumatoid arthritis. Additionally, Cabiralizumab has been utilized in combination with Nivolumab in the exploration of therapeutic strategies for lung cancer, highlighting its potential in oncology research settings.
Cabiralizumab (FPA 008) is a monoclonal antibody targeting CSF1R (Colony Stimulating Factor 1 Receptor), designed to modulate the immune system by enhancing T cell infiltration and promoting antitumor immune responses. This antibody effectively inhibits the activation of osteoclasts, thereby preventing bone destruction, making it a valuable tool in the study of rheumatoid arthritis. Additionally, Cabiralizumab has been utilized in combination with Nivolumab in the exploration of therapeutic strategies for lung cancer, highlighting its potential in oncology research settings.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
